Drug for preventing thrombus formation and treating thrombus and preparation method thereof

A technology of thrombosis and drugs, applied in the direction of medical preparations containing active ingredients, drug combinations, pharmaceutical formulas, etc., can solve problems such as the risk of massive bleeding

Inactive Publication Date: 2016-08-31
李明
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although currently available treatment of thrombotic diseases has the above-mentioned multiple treatment options, these platelet inhibitors, anticoagulant and thrombolytic therapy have a greater risk of bleeding, especially the main complication of thrombolytic therapy is bleeding. Be especially wary of gastrointestinal tract, intracranial hemorrhage, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug for preventing thrombus formation and treating thrombus and preparation method thereof
  • Drug for preventing thrombus formation and treating thrombus and preparation method thereof
  • Drug for preventing thrombus formation and treating thrombus and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1, such as Figure 1a and Figure 1b As shown, the time curve of whole blood clot lysis provided by the present invention.

[0028]1 ml of blood was collected from the tail vein of SD rats and placed in a small test tube, which was placed in a 4°C refrigerator in a tilted position. When not adding anticoagulants, blood coagulation occurs because the fibrinogen in the plasma becomes fibrin, and the fibrin forms a blood clot together with blood cells, and what remains on the upper layer is serum. As a contrast, the supernatant serum in the test tube was removed, and 10 ml of 0.9% sodium chloride physiological saline was added. For AF-H, 10 ml of saline containing 167 mg of active site was added to a serum-depleted test tube, and for AF-L, 10 ml of physiological saline containing 16.7 mg of active site was added to a serum-depleted test tube. For ethanol-H, 10 ml of normal saline containing 833 mg of ethanol extract was added to a serum-depleted test tube, and fo...

Embodiment 2

[0029] Example 2, such as Figure 2a and Figure 2b As shown in , the compounds of different components provided by the present invention have the ability to dissolve blood clots in whole blood.

[0030] Add 10 ml of 0.9% sodium chloride saline to the thrombus test tube containing 1 ml of blood. AF-H is to add 10ml of normal saline containing 167mg of active site to a test tube containing the same amount of thrombus as the control, and AF-L is to add 10ml of physiological saline containing 16.7mg of active site to a test tube containing the same amount of thrombus . Ethanol-H is to add 10ml of physiological saline containing 833mg ethanol extract to the test tube containing the same amount of thrombus, and ethanol-L is to add 10ml of physiological saline containing 83.3mg ethanol extract to the test tube containing the same amount of thrombus brine. Polyphenol-H is to add 10ml of physiological saline containing 167mg of total polyphenols of Myrica pilosa to the test tube c...

Embodiment 3

[0031] Example 3, such as image 3 Shown is the therapeutic effect of the active site of the oral compound provided by the present invention on patients with microthrombosis. No. 1-4 are 4 different darkfield (Brooker microscope) peripheral blood blood smears with microthrombosis in the blood, respectively. The blood smear (upper row of smears) at the patient's initial visit shows microthrombosis (the red circle contains the area). The patient's blood cells also clumped and adhered to each other into clumps or strings. However, after one week of oral treatment with the active site (1 gram each time, twice a day) to the patient (middle row smear 1 week), it can be seen that all four patients did not find any microthrombosis in the blood smear, and the severely agglutinated blood cells also improved significantly . After two weeks of treatment (lower smear 2week), not only did no microthrombosis be found in the blood smears of all four patients, but the agglutination state o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a drug for preventing thrombus formation and treating thrombus and a preparation method thereof. The drug for preventing thrombus formation and treating thrombus is a compound active part extracted from geum japonicum. The compound active part comprises at least one of polysacharide compounds, polyphenol compounds, flavonoid compounds and triterpene compounds. The compound active part is extracted from geum japonicum and acts on the human body so that thrombus formation is prevented and formed thrombus is treated. Through inhibiting thrombus formation and dissolving thrombus, the compound active part can prevent and treat thrombus formation-caused diseases in different tissue or organs.

Description

technical field [0001] The patent relates to the pharmaceutical field, in particular to a medicine for preventing and treating thrombus and a preparation method thereof. Background technique [0002] Thrombosis is the formation of abnormal blood clots in the circulatory system by formed elements in the blood, or deposits of blood on the walls of blood vessels and the inner lining of the heart. The most common cardiovascular and cerebral thromboembolic diseases are one of the important causes of death and disability in the world population. Others include deep vein thrombosis leading to pulmonary embolism, portal vein thrombosis leading to portal hypertension, superficial thrombophlebitis, deep vein thrombosis of the lower extremities, mesenteric artery embolism, and limb arterial embolism. The ways of thrombus formation in the circulatory system can be roughly divided into: ① subintimal exposure and exogenous substances activate platelet aggregation; ② fibrin deposition. G...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/74A61P7/02A61P9/10
Inventor 李明
Owner 李明
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap